News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
522,774 Results
Type
Article (12675)
Company Profile (145)
Press Release (509953)
Multimedia
Podcasts (99)
Webinars (10)
Section
Business (175944)
Career Advice (425)
Deals (27123)
Drug Delivery (79)
Drug Development (57652)
Employer Resources (19)
FDA (10884)
Job Trends (9480)
News (254587)
Policy (21780)
Tag
2025 Best Places to Work (1)
2026 Best Places to Work (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (8)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (3)
2027 Genetown Premier (1)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (704)
Accelerated approval (40)
ADA (31)
Adcomms (6)
Allergies (120)
Alliances (35214)
ALS (161)
Alzheimer's disease (1272)
Antibody-drug conjugate (ADC) (387)
Approvals (11616)
Artificial intelligence (454)
ASCO (184)
Autoimmune disease (268)
Automation (39)
Bankruptcy (277)
Belgium (7)
Best Places to Work (7662)
BIO (42)
Biologics (49)
BIOSECURE Act (3)
Biosimilars (165)
BioSpace Insights (27)
Biotechnology (92)
Bispecific (25)
Bladder cancer (160)
Brain cancer (51)
Breast cancer (586)
Cancer (4456)
Cardiovascular disease (330)
Career advice (349)
Career pathing (6)
CAR-T (209)
CDC (9)
CDMO (66)
Celiac Disease (3)
Cell therapy (578)
Cervical cancer (37)
Clinical research (52309)
Collaboration (1564)
Commercialization (31)
Compensation (1623)
Complete response letters (47)
COVID-19 (1132)
CRISPR (75)
C-suite (962)
Cystic fibrosis (100)
Data (6874)
Denatured (5)
Depression (123)
Dermatology (122)
Diabetes (540)
Diagnostics (4523)
Digital health (46)
Diversity (2)
Diversity, equity & inclusion (6)
Drug discovery (222)
Drug pricing (110)
Drug shortages (32)
Duchenne muscular dystrophy (206)
Earnings (77281)
Editorial (26)
Employer branding (3)
Employer resources (22)
ESMO (249)
Events (92996)
Executive appointments (819)
Eye disease (3)
FDA (14088)
Fibrodysplasia Ossificans Progressiva (13)
Fragile X (1)
Friedreich's ataxia (21)
Frontotemporal dementia (29)
Funding (1194)
Gene editing (159)
Generative AI (28)
Gene therapy (430)
GLP-1 (910)
Government (2532)
Grass and pollen (3)
Guidances (306)
Healthcare (10641)
Hematology (101)
HIV (66)
Huntington's disease (35)
Idiopathic pulmonary fibrosis (6)
IgA nephropathy (87)
Immunology and inflammation (167)
Immuno-oncology (87)
Indications (203)
Infectious disease (1365)
Inflammatory bowel disease (162)
Inflation Reduction Act (8)
Influenza (93)
Intellectual property (283)
Interviews (64)
IPO (12953)
IRA (16)
Job creations (2188)
Job search strategy (324)
JPM (27)
Kidney cancer (24)
Kidney disease (92)
Labor market (22)
Layoffs (129)
Leadership (9)
Legal (5649)
Licensing (57)
Liver cancer (55)
Longevity (31)
Lung cancer (623)
Lung diease (9)
Lymphoma (309)
Machine learning (39)
Management (5)
Manufacturing (826)
Marketing (23)
MASH (148)
Medical affairs (3)
Medical device (9440)
Medtech (9639)
Mergers & acquisitions (15322)
Metabolic disorders (1417)
mRNA (121)
Multiple sclerosis (132)
Multispecific (3)
NASH (10)
Netherlands (7)
Neurodegenerative disease (330)
Neuropsychiatric disorders (59)
Neuroscience (2383)
Neurotech (3)
NextGen: Class of 2026 (3421)
Non-profit (1305)
Now hiring (46)
Obesity (706)
Opinion (72)
Ovarian cancer (206)
Pain (217)
Pancreatic cancer (250)
Parkinson's disease (244)
Partnered (13)
Patents (558)
Patient advocacy (3)
Patient recruitment (601)
Patient selection (53)
Peanut (42)
People (43955)
Peptides (19)
Pharmaceutical (32)
Pharmacy benefit managers (13)
Phase 1 (16443)
Phase 2 (23021)
Phase 3 (16641)
Pipeline (9239)
Policy (120)
Postmarket research (1795)
Preclinical (6877)
Press Release (40)
Prostate cancer (233)
Psychedelics (38)
Radiopharmaceuticals (266)
Rare diseases (721)
Real estate (3297)
Recruiting (11)
Regenerative medicine (13)
Regulatory (17746)
Reports (35)
Research institute (787)
Resumes & cover letters (60)
Rett syndrome (49)
RNA editing (16)
RSV (55)
Schizophrenia (139)
Series A (211)
Series B (157)
Service/supplier (6)
Sickle cell disease (72)
Special edition (18)
Spinal muscular atrophy (100)
Sponsored (11)
Startups (2221)
Stem cells (2)
Stomach cancer (3)
Substance use disorders (20)
Supply chain (89)
Tariffs (66)
The Weekly (94)
Vaccines (519)
Venture capital (55)
Weight loss (511)
Wet AMD (3)
Women's health (112)
Women in leadership (1)
Worklife (2)
Date
Last 7 days (528)
Last 30 days (1819)
Last 365 days (21047)
2026 (17595)
2025 (20951)
2024 (24737)
2023 (28295)
2022 (37428)
2021 (40673)
2020 (36802)
2019 (26232)
2018 (19819)
2017 (20456)
2016 (19562)
2015 (25885)
2014 (22733)
2013 (18996)
2012 (20989)
2011 (21260)
2010 (21068)
Location
Africa (315)
Alabama (84)
Alaska (3)
Arizona (328)
Arkansas (12)
Asia (20502)
Australia (2712)
California (13241)
Canada (4005)
China (717)
Colorado (564)
Connecticut (467)
Delaware (246)
Europe (32104)
Florida (1986)
Georgia (418)
Hawaii (3)
Idaho (49)
Illinois (831)
India (81)
Indiana (632)
Iowa (26)
Japan (497)
Kansas (110)
Kentucky (33)
Louisiana (30)
Maine (29)
Maryland (1353)
Massachusetts (8800)
Michigan (325)
Minnesota (617)
Mississippi (5)
Missouri (104)
Montana (21)
Nebraska (14)
Nevada (139)
New Hampshire (70)
New Jersey (3164)
New Mexico (13)
New York (3133)
North Carolina (1453)
North Dakota (4)
Northern California (6705)
Ohio (335)
Oklahoma (15)
Oregon (21)
Pennsylvania (2517)
Puerto Rico (28)
Rhode Island (34)
South America (499)
South Carolina (83)
South Dakota (1)
Southern California (5492)
Tennessee (135)
Texas (2221)
United States (43807)
Utah (401)
Vermont (2)
Virginia (178)
Washington D.C. (51)
Washington State (1020)
West Virginia (1)
Wisconsin (85)
Wyoming (1)
522,774 Results for "eli lilly canada inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Editorial
Eli Lilly and the LA Dodgers: A tale of 2 dynasties
Watching the baseball playoffs this week, I was struck by the parallels between the Los Angeles Dodgers and Eli Lilly. Both franchises spend a lot of money and always appear to come out on top.
October 8, 2026
·
3 min read
·
Heather McKenzie
Diabetes
Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss
Eli Lilly’s next-gen weight loss drug retatrutide soundly beat Novo’s approved medicine Ozempic in weight loss and blood sugar reduction, padding the case for a regulatory application that’s expected in the first quarter of 2027.
October 28, 2026
·
3 min read
·
Annalee Armstrong
Earnings
Lilly’s guidance has jumped by $10B as GLP-1 sales keep blowing past expectations
With the commercial business performing so well, Eli Lilly is eyeing earlier business development bets to build out a longer-term pipeline.
October 29, 2026
·
3 min read
·
Annalee Armstrong
Earnings
Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellers
Eli Lilly’s shares rose 4% in early morning trading after reporting revenue of $24.4 billion, well past consensus estimates.
October 29, 2026
·
1 min read
·
Annalee Armstrong
Manufacturing
Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program
Teams at facilities being developed by Eli Lilly, Regeneron and other companies will receive early technical guidance and additional perks from the FDA.
July 1, 2026
·
2 min read
·
Nick Paul Taylor
Obesity
Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
EloraTZP—a combination of an amylin asset and Eli Lilly’s approved obesity drug Zepbound—made a clean sweep of the primary and secondary endpoints in a mid-stage trial of adults with obesity and type 2 diabetes, setting up the launch of a Phase 3 trial before the end of the year.
September 30, 2026
·
3 min read
·
Heather McKenzie
Layoffs
Foghorn lays off 40% of staff after Lilly collaboration ends
Foghorn Therapeutics and Eli Lilly teamed up in 2021 to develop and commercialize oncology products. The biotech’s layoffs will leave the company with 65 employees as it refocuses on its proprietary portfolio programs.
October 1, 2026
·
2 min read
·
Angela Gabriel
Weight loss
Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
Eli Lilly’s weight loss pill Foundayo has had a “slower-than-hoped” launch, according to BMO Capital Markets, which contended that the indirect comparison data—despite falling short of definitive proof of superiority—could help the Indiana giant build momentum for its oral drug.
September 30, 2026
·
3 min read
·
Tristan Manalac
Legal
Nektar prevails in legal battle with Lilly over broken rezpeg partnership
Nektar Therapeutics has been awarded $90 million in damages after a jury sided with the biotech, which had accused Big Pharma Eli Lilly of “botching” an analysis of their formerly partnered autoimmune drug.
September 25, 2026
·
2 min read
·
Annalee Armstrong
China
Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
InnoCare Pharma is the latest addition to Eli Lilly’s dealmaking spree, which includes some of the biggest acquisitions this year: up to $7 billion for Kelonia Therapeutics in April and up to $7.8 billion for Centessa Pharmaceuticals in March.
September 24, 2026
·
1 min read
·
Tristan Manalac
1 of 52,278
Next